P21 (P021)

P21 (widely referred to as P021 in scientific literature) from Super Human Peptides UK is a highly advanced, synthetic neurogenic peptide. It is a precise mimetic derived from the most active neurogenic region of the naturally occurring Ciliary Neurotrophic Factor (CNTF), specifically mapping to amino acid residues 148-151 (DGGL). In laboratory research, P21 serves as a premier model for investigating profound neurogenesis, synaptogenesis, and the reversal of severe cognitive decline.

Researchers utilize this peptide because it possesses a unique adamantane modification, rendering it highly lipophilic and exceptionally capable of crossing the blood-brain barrier. Once active in the central nervous system, P21 works by competitively inhibiting the Leukemia Inhibitory Factor (LIF) signaling pathway, which in turn un-silences neurogenic signals and drastically increases the expression of Brain-Derived Neurotrophic Factor (BDNF). Produced under GMP-compliant conditions and verified for 99% purity or higher, P21 is an elite tool for advanced preclinical research into Alzheimer's disease models, tauopathy, and structural brain repair.

• —CNTF Mimetic: Synthetically derives the most potent neuro-regenerative sequence from Ciliary Neurotrophic Factor.
• —BBB Permeability: Specifically engineered with an adamantylated group to guarantee extreme blood-brain barrier penetration and resist plasma degradation.
• —LIF Inhibition: Competitively blocks the Leukemia Inhibitory Factor pathway to promote the maturation of neural progenitor cells.
• —BDNF Amplification: Triggers a massive, sustained up-regulation of Brain-Derived Neurotrophic Factor in the hippocampus.
• —High Purity: 99% purity or higher (verified by HPLC and MS analysis).
• —Quality Standard: GMP / ISO certified manufacturing.

• —Dentate Gyrus Neurogenesis: Studying the rapid formation, survival, and maturation of new neural progenitor cells (NPCs) into functional neurons in the hippocampus.
• —Tau Pathology: Preclinical models investigating the significant reduction of abnormal hyperphosphorylation of Tau proteins, a primary hallmark of neurodegeneration.
• —Amyloid Beta Clearance: Researching the peptide's ability to prevent the deposition and accelerate the clearance of extracellular Aβ plaques in aged animal models.
• —Synaptic Compensation: Measuring the physical restoration of dendritic spines and enhanced synaptic plasticity following chemically induced neuronal loss.
• —Adamantane Pharmacokinetics: Evaluating how the addition of an adamantylated moiety shields the short peptide chain from destructive exopeptidases while dictating central nervous system uptake.

The development of P21 (P021) was driven by the massive limitations of delivering natural neurotrophic factors (like BDNF or full-length CNTF) systemically. Large native proteins cannot successfully cross the blood-brain barrier and often trigger severe systemic immune responses. Researchers circumvented this by mapping the CNTF protein to find its most active 4-amino-acid neurogenic epitope, isolating it, and engineering it into a highly stable, adamantane-shielded small molecule.

Laboratory studies have consistently demonstrated staggering neuro-regenerative capabilities. In landmark transgenic animal models of Alzheimer's disease (such as the 3xTg-AD mouse model), the administration of P21 effectively rescued cognitive deficits and physically restored dendritic structures even in aged subjects. Most notably, researchers observed that chronic P21 administration not only boosted neurogenesis but directly reduced the levels of hyperphosphorylated Tau proteins and Beta-Amyloid plaques in both brain tissue and cerebrospinal fluid.

Because it targets the root health of the cellular network rather than merely managing neurotransmitter levels, it remains one of the most prioritized candidates in modern neurodegeneration research.

• 1.Kazim, S.F. et al., "Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease," Neurobiology of Disease, 2014.
• 2.Baazaoui, N. et al., "Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound," Alzheimer's Research & Therapy, 2017.
• 3.Li, B. et al., "Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice," FEBS Letters, 2010.
• 4.Khatoon, S. et al., "Elevated Tau Level in Aged Rat Cerebrospinal Fluid Reduced by Treatment with a Neurotrophic Compound," Journal of Alzheimer's Disease, 2015.